Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Siglec-E deletion alters AT macrophages phenotypes, induces an inflammatory response, and adipogenesis during diet-induced obesity.

Rakib A., Al Mamun MA., Mandal M., Yasmen N., Ofosu-Boateng M., Collier DM.

Animal Study on Chronic Inflammation, published in Int Immunopharmacol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Int Immunopharmacol (2025)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
41343943
PMCID
PMC12696692
DOI
10.1016/j.intimp.2025.115952
Citations
1

Abstract (original English)

Obesity is currently a worldwide health problem, affecting more than 600 million people, and poses a threat to lifestyle and triggers metabolic complications. The infiltration of macrophages into adipose tissue (AT) plays a key role in inducing inflammation and multiple diseases during obesity. Therefore, comprehensive knowledge is required on the crosstalk between adipocytes with resident macrophages in AT to design therapeutic options for obesity and metabolic diseases. While we have demonstrated the role of Siglec-E in inflammation, the mechanism by which Siglec-E induces AT inflammation and adipogenesis remains unclear to date. Thus, this study describes how Siglec-E alters AT macrophages phenotypes, function, and adipogenesis using a high-fat diet (HFD)-induced model of obesity. We showed that during obesity, expression of Siglec-E orchestrated the infiltration of macrophages in the AT. Further, deletion of Siglec-E increased the frequency and expression of inflammatory markers and modulated macrophages towards M1 phenotypes to induce AT inflammation. We also noticed that interleukin (IL)-6 and monocyte chemoattractant protein 1 (MCP-1), inflammatory markers, increased in differentiated 3T3-L1 adipocytes after the inhibition of Siglec-E. Further, cultured 3T3-L1 adipocytes, treated with Siglec-E siRNA, show an increasing expression of peroxisome proliferator-activated rece

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMacrophagesObesityAdipogenesisMiceDiet, High-FatInflammationMice, Inbred C57BLAdipose Tissue3T3-L1 Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research